The aimof this study was to compare the levels of nesfatin-1 in healthy subjects with those in prediabetic and diabetic patients who have different glucose tolerance levels. Overall, 100 subjects were divided into
5 groups healthy control (C), impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), metabolic syndrome (MS) an type 2 diabetes mellitus, (Type2 DM).Glycated hemoglobin (HbA1c) assessed the glycemic
control. Homeostasis modelassessment of insulin resistance (HOMA
-IR) was determined using computer analyses. Nesfatin-1 levels were
measured using ELISA method. IFG and IGT (prediabetic groups)from MS and Type 2 DM (diabetic groups) differed significantly in HOMA-IR. The nesfatin-1 levels were lower, although not statistically significant, in IFG
(0.937±0.03 ng/ml, p=0.07) andIGT (1.039±0.06 ng/ml, p=0.5) groups compared to healthysubjects (1.094±0.07 ng/ml). However, the nesfatin-1 levelswere lower in patients with Type 2 DM (0.867±0.02 ng/ml, p=0.007) and MS (0.885±0.01ng/ml, p=0.01) compared to healthy subjects. Nesfatin-1 levels were significantly lower in diabetic patients compared to healthy
subjects. This studysupports the role of insulin resistance in decreased nesfatin-1 levels in patients with Type 2 DM and MS.